000298614 001__ 298614
000298614 005__ 20250216015205.0
000298614 0247_ $$2doi$$a10.1016/j.jgo.2025.102195
000298614 0247_ $$2pmid$$apmid:39919652
000298614 0247_ $$2ISSN$$a1879-4068
000298614 0247_ $$2ISSN$$a1879-4076
000298614 0247_ $$2altmetric$$aaltmetric:174093234
000298614 037__ $$aDKFZ-2025-00314
000298614 041__ $$aEnglish
000298614 082__ $$a610
000298614 1001_ $$aLi, Keva$$b0
000298614 245__ $$aAge-stratified analysis of health-related quality of life in patients with early-stage breast cancer receiving adjuvant radiation therapy and endocrine therapy.
000298614 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000298614 3367_ $$2DRIVER$$aarticle
000298614 3367_ $$2DataCite$$aOutput Types/Journal article
000298614 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1739198492_28365
000298614 3367_ $$2BibTeX$$aARTICLE
000298614 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000298614 3367_ $$00$$2EndNote$$aJournal Article
000298614 520__ $$aHealth-related quality of life (HRQoL) in older patients with breast cancer (BC) (≥70 years) is not well studied. This study assesses aging-related differences in patient-reported outcomes among estrogen receptor-positive (ER+) patients with BC treated with breast conservation surgery (BCS), radiation therapy (RT), and endocrine therapy (ET).Among the 2,057 patients with ER+ early-stage BC enrolled in the prospective multicenter REQUITE study, 1,003 patients receiving adjuvant RT + ET as the only systemic therapy constitute our study population. Patients were stratified by age into younger (<70 years, n = 810 patients) and older (≥70 years, n = 193 patients) groups. Prospectively collected HRQoL was measured using the validated European Organization for Research and Treatment of Cancer (EORTC) quality of life of cancer patients (QLQ-30) and breast cancer-specific quality of life (QLQ-BR23), and Multidimensional Fatigue Inventory (MFI-20) measures at baseline following BCS and pre-adjuvant treatment, post-RT, and at one-year, two-year, and three-year intervals. Statistical analysis involved a mixed model analysis of variance, weighted by propensity scoring.Older patients had a higher burden of comorbidities, larger tumor size, and higher rates of N1 disease compared to the younger group. RT boost to the lumpectomy site was more often delivered in younger participants (72 %) compared to older (50 %). Younger patients predominately received tamoxifen (63.5 %), while older patients more commonly received aromatase inhibitors (67.4 %). Throughout the follow-up, we observed that the younger patients showed greater recovery in QoL domains including sexual enjoyment, systemic side effects, breast symptoms, global health status, and emotional, physical, and social functioning compared to the older group. Cognitive function, which declined from baseline in both groups, improved over time in younger participants but persisted at lower levels in older patients at the three-year follow-up period.Adjuvant treatments differentially impacted HRQoL, with older patients experiencing greater and more persistent adverse effects compared to younger counterparts. These findings underscore the need for tailored interventions that address the unique challenges in HRQoL recovery among older BC survivors.
000298614 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000298614 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000298614 650_7 $$2Other$$aEarly-stage breast cancer, estrogen receptor positive
000298614 650_7 $$2Other$$aEndocrine therapy
000298614 650_7 $$2Other$$aHealth-related quality of life
000298614 650_7 $$2Other$$aLumpectomy
000298614 650_7 $$2Other$$aOlder women
000298614 650_7 $$2Other$$aPatient-reported outcomes
000298614 650_7 $$2Other$$aRadiation therapy
000298614 7001_ $$aChadha, Manjeet$$b1
000298614 7001_ $$aMoshier, Erin$$b2
000298614 7001_ $$aRosenstein, Barry S$$b3
000298614 7001_ $$aconsortium, REQUITE$$b4$$eCollaboration Author
000298614 7001_ $$aJandu, Harkeran K$$b5$$eContributor
000298614 7001_ $$aVeal, Colin D$$b6$$eContributor
000298614 7001_ $$aFachal, Laura$$b7$$eContributor
000298614 7001_ $$aLuccarini, Craig$$b8$$eContributor
000298614 7001_ $$aAguado-Barrera, Miguel E$$b9$$eContributor
000298614 7001_ $$aAltabas, Manuel$$b10$$eContributor
000298614 7001_ $$aAzria, David$$b11$$eContributor
000298614 7001_ $$aBaten, Adinda$$b12$$eContributor
000298614 7001_ $$aBourgier, Celine$$b13$$eContributor
000298614 7001_ $$aBultijnck, Renée$$b14$$eContributor
000298614 7001_ $$aColciago, Riccardo R$$b15$$eContributor
000298614 7001_ $$aFarcy-Jacquet, Marie-Pierre$$b16$$eContributor
000298614 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b17$$eContributor
000298614 7001_ $$aChoudhury, Ananya$$b18$$eContributor
000298614 7001_ $$aDunning, Alison$$b19$$eContributor
000298614 7001_ $$aElliott, Rebecca M$$b20$$eContributor
000298614 7001_ $$aGreen, Sheryl$$b21$$eContributor
000298614 7001_ $$aGutiérrez-Enríquez, Sara$$b22$$eContributor
000298614 7001_ $$aHerskind, Carsten$$b23$$eContributor
000298614 7001_ $$aLambrecht, Maarten$$b24$$eContributor
000298614 7001_ $$aMonten, Christel$$b25$$eContributor
000298614 7001_ $$aRancati, Tiziana$$b26$$eContributor
000298614 7001_ $$aReyes, Victoria$$b27$$eContributor
000298614 7001_ $$aDe Ruysscher, Dirk$$b28$$eContributor
000298614 7001_ $$aDe Santis, Maria Carmen$$b29$$eContributor
000298614 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b30$$eContributor
000298614 7001_ $$aSperk, Elena$$b31$$eContributor
000298614 7001_ $$aVeldwijk, Marlon R$$b32$$eContributor
000298614 7001_ $$aSymonds, R Paul$$b33$$eContributor
000298614 7001_ $$aStobart, Hilary$$b34$$eContributor
000298614 7001_ $$aTaboada-Valladares, Begoña$$b35$$eContributor
000298614 7001_ $$aVega, Ana$$b36$$eContributor
000298614 7001_ $$aVeldeman, Liv$$b37$$eContributor
000298614 7001_ $$aWebb, Adam J$$b38$$eContributor
000298614 7001_ $$aWeltens, Caroline$$b39$$eContributor
000298614 7001_ $$aWest, Catharine M$$b40$$eContributor
000298614 7001_ $$aRattay, Tim$$b41$$eContributor
000298614 7001_ $$aTalbot, Christopher J$$b42$$eContributor
000298614 773__ $$0PERI:(DE-600)2556813-9$$a10.1016/j.jgo.2025.102195$$gVol. 16, no. 2, p. 102195 -$$n2$$p102195$$tJournal of geriatric oncology$$v16$$x1879-4068$$y2025
000298614 909CO $$ooai:inrepo02.dkfz.de:298614$$pVDB
000298614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000298614 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b30$$kDKFZ
000298614 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000298614 9141_ $$y2025
000298614 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ GERIATR ONCOL : 2022$$d2024-12-16
000298614 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000298614 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000298614 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000298614 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000298614 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000298614 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000298614 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000298614 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-16
000298614 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000298614 980__ $$ajournal
000298614 980__ $$aVDB
000298614 980__ $$aI:(DE-He78)C020-20160331
000298614 980__ $$aUNRESTRICTED